中药ETF(159647)涨超2.5%，八部门发文支持重点中药工业全产业链发展

Group 1 - The core viewpoint of the news is the collective rise of traditional Chinese medicine (TCM) stocks following the release of the "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" by eight departments including the Ministry of Industry and Information Technology on February 5, 2026 [1] - The plan outlines six key tasks: improving raw material quality and supply stability, collaborative innovation, enhancing manufacturing capabilities, revitalizing the national medicine industry, and cultivating outstanding enterprises [1] - By 2030, the goal is to promote a number of innovative TCM drugs to be approved for market launch and to cultivate ten major varieties of traditional Chinese medicine [1] Group 2 - The upcoming release of the new essential drug catalog in 2026 is expected to include approximately 40% traditional Chinese medicine products, which will serve as a core policy driver for the growth of innovative TCM drugs [1] - The market is witnessing a resurgence of old TCM brands while new brands are gradually emerging, supported by the cleaning up of TCM licenses and resource allocation towards established brands [1] - As of February 6, 2026, the CSI Traditional Chinese Medicine Index (930641) rose by 2.45%, with significant increases in stocks such as Panlong Pharmaceutical (up 10.01%) and Longshen Rongfa (up 9.99%) [1] Group 3 - The CSI Traditional Chinese Medicine Index closely tracks the performance of listed companies involved in the production and sales of TCM [2] - As of January 30, 2026, the top ten weighted stocks in the CSI Traditional Chinese Medicine Index accounted for 55.13% of the index, including companies like Yunnan Baiyao and Tongrentang [2]